SCHEMBL11943918

SCHEMBL11943918

CCC(=O)OCCOc1c(N2CCN(S(=O)(=O)Cc3ccccc3)CC2)cnn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.47
▸ CYP2C19 P33261 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ GPR183 P32249 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ DCTPP1 Q9H773 2/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.39
▸ POLB P06746 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ NCOA2 Q15596 1/20 0.39
▸ NCOA1 Q15788 1/20 0.39
▸ NCOA3 Q9Y6Q9 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943913 0.88 MAPT (0.48) MAPTCYP2C19GAAGPR183ALDH1A1
SCHEMBL11945010 0.85 MAPT (0.52) MAPTCYP2C19TSHRGAAGPR183
SCHEMBL11944989 0.84 MAPT (0.52) MAPTCYP2C19GAAALDH1A1DCTPP1
SCHEMBL11944102 0.83 MAPT (0.54) MAPTALDH1A1DCTPP1POLBKMT2A
SCHEMBL11943544 0.83 MAPT (0.56) MAPTCYP2C19TSHRGAAALDH1A1
SCHEMBL11945310 0.82 MAPT (0.42) MAPTCYP2C19TSHRGAAALDH1A1
SCHEMBL11944009 0.82 MAPT (0.47) MAPTCYP2C19TSHRGAAALDH1A1
SCHEMBL11944240 0.81 MAPT (0.61) MAPTCYP2C19TSHRGAAALDH1A1
SCHEMBL11945432 0.81 MAPT (0.41) MAPTCYP2C19TSHRGAAGPR183
SCHEMBL11943956 0.81 MAPT (0.49) MAPTCYP2C19TSHRGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885CYP2C19 461/4885TSHR 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback